ID24653A - Zat-zat terapi - Google Patents

Zat-zat terapi

Info

Publication number
ID24653A
ID24653A IDW991048A ID991048A ID24653A ID 24653 A ID24653 A ID 24653A ID W991048 A IDW991048 A ID W991048A ID 991048 A ID991048 A ID 991048A ID 24653 A ID24653 A ID 24653A
Authority
ID
Indonesia
Prior art keywords
optionally substituted
group
phenyl
alkyl group
formula
Prior art date
Application number
IDW991048A
Other languages
English (en)
Indonesian (id)
Inventor
David John Calderwood
David Norman Johnston
Paul Rafferty
Helen Louise Twigger
Rainer Munschauer
Lee Arnold
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ID24653A publication Critical patent/ID24653A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW991048A 1997-03-19 1998-03-09 Zat-zat terapi ID24653A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4083697P 1997-03-19 1997-03-19

Publications (1)

Publication Number Publication Date
ID24653A true ID24653A (id) 2000-07-27

Family

ID=21913242

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991048A ID24653A (id) 1997-03-19 1998-03-09 Zat-zat terapi

Country Status (23)

Country Link
US (1) US6001839A (fr)
EP (1) EP0970084B1 (fr)
JP (1) JP2001516353A (fr)
KR (1) KR20000076426A (fr)
CN (1) CN1134439C (fr)
AT (1) ATE242245T1 (fr)
AU (1) AU748884B2 (fr)
BG (1) BG64282B1 (fr)
BR (1) BR9808281A (fr)
CA (1) CA2283961A1 (fr)
DE (1) DE69815317T2 (fr)
DK (1) DK0970084T3 (fr)
ES (1) ES2202827T3 (fr)
HU (1) HUP0001507A3 (fr)
ID (1) ID24653A (fr)
IL (1) IL131582A0 (fr)
NO (1) NO313962B1 (fr)
NZ (1) NZ337529A (fr)
PL (1) PL335685A1 (fr)
PT (1) PT970084E (fr)
SK (1) SK125999A3 (fr)
TR (1) TR199902301T2 (fr)
WO (1) WO1998041525A1 (fr)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
WO2000012089A1 (fr) * 1998-08-31 2000-03-09 Merck & Co., Inc. Nouveaux inhibiteurs d'angiogenese
ID29028A (id) * 1998-09-18 2001-07-26 Basf Ag Pirolopirimidina sebagai penghambat protein kinase
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6265403B1 (en) * 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
KR20020063854A (ko) * 1999-09-17 2002-08-05 애보트 게엠베하 운트 콤파니 카게 치료제로서의 키나제 억제제
MXPA02002898A (es) 1999-09-17 2003-10-14 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7369946B2 (en) 2000-03-29 2008-05-06 Abbott Gmbh & Co. Kg Method of identifying inhibitors of Tie-2
CA2404532A1 (fr) * 2000-03-29 2001-10-04 Nancy J. Bump Procede d'identification des inhibiteurs de tie-2
WO2001072751A1 (fr) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
KR100403860B1 (ko) * 2000-12-27 2003-11-01 엘지전자 주식회사 차세대 이동통신 시스템의 접속시도시의 충돌감소를 위한알에이씨에이치 선택방법
TWI238824B (en) * 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
AP2003002929A0 (en) * 2001-06-23 2003-12-31 Aventis Pharma Inc Pyrrolopyrimidines as protein kinase inhibitors
US20040266771A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of tyrosine kinase inhibitors for treating bone loss
WO2003002106A2 (fr) 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques
US7678805B2 (en) 2001-06-29 2010-03-16 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
US20040259892A1 (en) * 2001-06-29 2004-12-23 Alain Moussy Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
WO2003003006A2 (fr) 2001-06-29 2003-01-09 Ab Science Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
US7741335B2 (en) 2001-06-29 2010-06-22 Ab Science Use of tyrosine kinase inhibitors for treating inflammatory diseases
DE60227709D1 (de) * 2001-06-29 2008-08-28 Ab Science Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
WO2004100868A2 (fr) * 2003-04-23 2004-11-25 Abbott Laboratories Procede servant a traiter le rejet d'un transplant
EP1620094A4 (fr) * 2003-05-06 2010-04-28 Glaxosmithkline Llc Nouveaux composes chimiques
US7429596B2 (en) * 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
BRPI0416656A (pt) * 2003-11-17 2007-01-16 Pfizer Prod Inc compostos de pirrolopirimidina úteis no tratamento do cáncer
EP1730148A4 (fr) * 2004-02-03 2009-08-19 Abbott Lab Utilisation d'aminobenzoxazoles comme agents therapeutiques
GB0403606D0 (en) * 2004-02-18 2004-03-24 Novartis Ag Organic compounds
CA2566160C (fr) * 2004-05-27 2011-01-18 Pfizer Products Inc. Derives pyrrolopyrimidiniques convenant au traitement du cancer
JP2008520744A (ja) 2004-11-19 2008-06-19 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 抗炎症性ピラゾロピリミジン
CA2601766A1 (fr) * 2005-03-17 2006-09-28 Novartis Ag N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2, 4, 4b-triazafluoren-9-yle)-phenyl] benzamides utilises en tant qu'inhibiteurs de tyrosine/threonine kinase, en particulier la b-raf kinase
CN101801971A (zh) * 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 可用作janus激酶抑制剂的脱氮嘌呤
PT2385053E (pt) 2005-11-17 2013-12-17 Osi Pharm Inc Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
EP1983971A4 (fr) * 2006-01-25 2010-11-24 Synta Pharmaceuticals Corp Composés aromatiques substitués destinés à des utilisations contre des inflammations et des troubles immunitaires
US7659274B2 (en) * 2006-01-25 2010-02-09 Osi Pharmaceuticals, Inc. Unsaturated mTOR inhibitors
CA2909277A1 (fr) 2006-04-04 2007-10-11 Kevan M. Shokat Antagonistes de la kinase
CL2007002617A1 (es) 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
EP1969934A1 (fr) * 2007-03-12 2008-09-17 Bayer CropScience AG Phénoxyphénylamidine substituée par 4 cycloalkyl ou 4 aryl et son utilisation en tant que fongicide
SG10202107066WA (en) * 2007-03-28 2021-07-29 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965336B (zh) 2008-01-04 2015-06-17 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
WO2009114870A2 (fr) 2008-03-14 2009-09-17 Intellikine, Inc. Inhibiteurs de kinases, et procédés d’utilisation associés
AU2009225614A1 (en) * 2008-03-19 2009-09-24 Osi Pharmaceuticals, Inc mTOR inhibitor salt forms
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
JP5819195B2 (ja) * 2008-10-16 2015-11-18 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 融合環ヘテロアリールキナーゼ阻害剤
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (fr) 2009-05-07 2010-11-11 Intellikine, Inc. Composés hétérocycliques et leurs utilisations
US7718662B1 (en) * 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
CA2799579A1 (fr) 2010-05-21 2011-11-24 Intellikine, Inc. Composes chimiques, compositions et procedes pour modulation de kinases
AU2011261185A1 (en) 2010-06-03 2013-01-10 Pharmacyclics, Inc. The use of inhibitors of Bruton's tyrosine kinase (Btk)
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2694509B1 (fr) * 2011-04-05 2016-05-18 Pfizer Limited Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine
WO2013010136A2 (fr) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2734530A1 (fr) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013077921A2 (fr) 2011-09-02 2013-05-30 The Regents Of The University Of California Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2871926A1 (fr) 2012-05-03 2013-11-07 Saint Louis College Of Pharmacy Compositions et procedes pour augmenter des peptides neurotrophiques
US9540382B2 (en) 2012-06-04 2017-01-10 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
KR20150032340A (ko) 2012-07-24 2015-03-25 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제(btk)의 억제제에 대한 내성과 관련된 돌연변이
EP2689778A1 (fr) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Dérivés de type azaindazole ou diazaindazole pour le traitement de la douleur
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
MA38183A1 (fr) 2012-11-15 2017-03-31 Pharmacyclics Inc Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN103333096A (zh) * 2013-06-25 2013-10-02 苏州大学 一种化学选择性制备多功能吡咯衍生物的新方法
KR20160062103A (ko) 2013-09-30 2016-06-01 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
CN105793255B (zh) 2013-10-04 2018-11-16 无限药品股份有限公司 杂环化合物及其用途
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2942528A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics Inc. Mutations de phospholipase c gamma 2 et associees aux resistances
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016019233A1 (fr) 2014-08-01 2016-02-04 Pharmacyclics Llc Inhibiteurs de la tyrosine kinase de bruton
CN106573002A (zh) 2014-08-07 2017-04-19 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂的新型制剂
WO2016054491A1 (fr) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
RS65234B1 (sr) 2015-03-03 2024-03-29 Pharmacyclics Llc Farmaceutske formulacije inhibitora brutonove tirozin kinaze
US10550124B2 (en) 2015-08-13 2020-02-04 San Diego State University Foundation Atropisomerism for increased kinase inhibitor selectivity
WO2017048702A1 (fr) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (fr) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
ES2964781T3 (es) 2016-06-21 2024-04-09 Nerviano Medical Sciences Srl Derivados de sulfonamida n-fenilsustituida como inhibidores de la cinasa
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
CN117510405A (zh) 2017-04-18 2024-02-06 礼来公司 苯基-2-羟基-乙酰氨基-2-甲基-苯基化合物
JP2021535113A (ja) * 2018-08-22 2021-12-16 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. ピロロ−アミノ−ピリダジノン化合物およびその中間体の調製方法
WO2020208139A1 (fr) * 2019-04-10 2020-10-15 Cellestia Biotech Ag Inhibiteurs de la voie de signalisation notch et leur utilisation dans le traitement de cancers
PE20220573A1 (es) 2019-05-13 2022-04-20 Relay Therapeutics Inc Inhibidores de fgfr y metodos de uso de los mismos
CN110483523B (zh) * 2019-08-27 2022-11-22 药雅科技(上海)有限公司 一种吡唑并嘧啶衍生物表皮生长因子抑制剂及其制备方法与用途
CA3152508A1 (fr) * 2019-08-29 2021-03-04 Hibercell, Inc. Composes de pyrrolopyrimidine inhibiteurs de perk
WO2021038540A1 (fr) 2019-08-31 2021-03-04 Sun Pharma Advanced Research Company Limited Acides cycloalkylidènecarboxyliques et dérivés en tant qu'inhibiteurs de la btk
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
TW202233625A (zh) * 2020-11-18 2022-09-01 美商傳達治療有限公司 Ｆｇｆｒ抑制劑及其製造及使用方法
EP4247795A1 (fr) 2020-11-18 2023-09-27 Deciphera Pharmaceuticals, LLC Inhibiteurs des kinases gcn2 et perk et leurs méthodes d'utilisation
CA3231948A1 (fr) * 2021-09-23 2023-03-30 Jingyu Hu Inhibiteurs de fgfr et leurs procedes d'utilisation
WO2023104035A1 (fr) * 2021-12-06 2023-06-15 英矽智能科技(上海)有限公司 Composé hétérocyclique monocyclique ou bicyclique substitué, son procédé de préparation et son utilisation médicale
CN116903628A (zh) * 2022-04-20 2023-10-20 深圳福沃药业有限公司 Fgfr2抑制剂及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834469A (en) * 1994-06-09 1998-11-10 Smithkline Beecham Corporation Endothelin receptor antagonists
JP4145955B2 (ja) * 1994-09-29 2008-09-03 ノバルティス アクチェンゲゼルシャフト ピロロ〔２，３−ｄ〕ピリミジン及びその使用
US5639757A (en) * 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5665721A (en) * 1995-06-07 1997-09-09 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
US6143749A (en) * 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CH690773A5 (de) * 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU1794697A (en) * 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
ES2203793T3 (es) * 1996-03-15 2004-04-16 Novartis Ag N-7-heterociclil-pirrolo(2,3-d)pirimidinas y su empleo.

Also Published As

Publication number Publication date
IL131582A0 (en) 2001-01-28
NZ337529A (en) 2000-10-27
TR199902301T2 (xx) 1999-12-21
KR20000076426A (ko) 2000-12-26
WO1998041525A1 (fr) 1998-09-24
BG103785A (en) 2000-06-30
HUP0001507A2 (hu) 2000-10-28
NO994509L (no) 1999-09-17
NO994509D0 (no) 1999-09-17
CN1134439C (zh) 2004-01-14
BG64282B1 (bg) 2004-08-31
JP2001516353A (ja) 2001-09-25
SK125999A3 (en) 2000-05-16
DE69815317D1 (de) 2003-07-10
PT970084E (pt) 2003-10-31
AU748884B2 (en) 2002-06-13
AU6829398A (en) 1998-10-12
PL335685A1 (en) 2000-05-08
CN1259950A (zh) 2000-07-12
ATE242245T1 (de) 2003-06-15
DK0970084T3 (da) 2003-09-29
BR9808281A (pt) 2000-05-16
US6001839A (en) 1999-12-14
EP0970084A1 (fr) 2000-01-12
CA2283961A1 (fr) 1998-09-24
DE69815317T2 (de) 2005-04-07
NO313962B1 (no) 2003-01-06
EP0970084B1 (fr) 2003-06-04
HUP0001507A3 (en) 2002-01-28
ES2202827T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
ID24653A (id) Zat-zat terapi
MX9203249A (es) Derivados del acido bencimidazolin-2-oxo-1-carboxilico y composiciones farmaceuticas que los contienen.
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
FI80877B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening.
FI810250L (fi) Foerfarande foer framstaellning av nya terapeutiskt aktiva heterocykliska foereningar
IL106387A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
TW429255B (en) Pyrazine compounds having treatment of central nervous system diseases and disorders
ES8106905A1 (es) Procedimiento para preparar derivados de benzodiazepina
ES8401073A1 (es) Un procedimiento para la preparacion de nuevos derivados de 3-triazolo (4,5-b) 1,5) benzodiazpezina.
MX9702259A (es) Derivados de quinoxalina utiles en terapia.
DK663588D0 (da) Hidtil ukendte forbindelser
ES2180201T3 (es) Derivados de azetidinona para el tratamiento de infecciones por hcmv.
MY118844A (en) 2,4,4-trisubstituted-1,3-dioxolane antifungals
EA200200292A1 (ru) Производные гигромицина
BG105126A (en) Tetrahydronaphthyridinyl-carboxamides have anti-convulsant activity
GB2005250A (en) (1-Alkylpyrrolyl-2)thio- acetamides
ECSP993235A (es) Antibioticos cetolidos carbamato y carbazato
ES2118977T3 (es) Derivados de aza-espiro-alcanos como agentes terapeuticos.